Goldline Pharmaceutical files Reg 29(2) disclosure for Swapan Khandelwal
On 24 June 2026 the company submitted a SEBI Substantial Acquisition of Shares filing indicating a share purchase by Swapan Khandelwal, details not disclosed in the announcement.
What Goldline Pharmaceutical announced
On 24 June 2026 Goldline Pharmaceutical Ltd (BSE: 544759) disclosed that it had received a filing under Regulation 29(2) of the SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011. The filing pertains to an acquisition of shares by Swapan Khandelwal. The brief announcement does not provide quantitative details such as the number of shares acquired, the percentage of total equity, or the purchase price.
Regulation 29(2) filing – what it means
Regulation 29(2) requires any person who acquires shares that cross the 5 % threshold (or any subsequent increase of 1 % or more) to disclose the acquisition to the stock exchange within two trading days. The purpose is to ensure transparency for investors and to trigger any mandatory takeover obligations if the shareholding exceeds 25 %.
The filing submitted by Goldline Pharmaceutical confirms compliance with this regulatory requirement. However, the public notice does not contain the specific shareholding figures, leaving those details to be examined in the underlying PDF filing.
Key facts at a glance
| Detail | Value |
|---|---|
| Company | Goldline Pharmaceutical Ltd |
| BSE ticker | 544759 |
| Filing date | 24 June 2026 |
| Regulation invoked | SEBI Reg. 29(2) – Substantial Acquisition of Shares & Takeovers |
| Acquirer | Swapan Khandelwal |
| Share‑holding details disclosed | Not provided in the announcement |
| Source | BSE filing (PDF) |
Why this matters for investors
The disclosure signals that a significant shareholder has entered the capital structure of Goldline Pharmaceutical. While the exact size of the stake is not disclosed, any acquisition that triggers Reg 29(2) typically indicates a holding of at least 5 % of the company's equity. Investors should monitor subsequent filings for the precise percentage, as larger holdings can influence corporate governance, voting outcomes, and potential future takeover scenarios.
Conclusion
Goldline Pharmaceutical has complied with SEBI’s disclosure requirements by filing a Reg 29(2) notice for Swapan Khandelwal on 24 June 2026. The announcement does not reveal the size of the shareholding, and interested parties will need to review the full filing for those specifics. Until further details emerge, the filing simply confirms a material share acquisition that may have implications for the company’s shareholder composition.
Frequently asked questions
Source filing: view original